| Literature DB >> 32953634 |
K Revathishree1, Sudarsan Shyam Sudhakar1, R Indu1, K Srinivasan1.
Abstract
Novel Coronavirus-disease-2019 (Covid-19) caused by the severe-acute-respiratory-syndrome coronavirus-2 (SARS-CoV-2) shows a rapid spread all over the world. It's still an ongoing pandemic with greater morbidity and mortality. In our study, we describe clinical features, and demographics of patients presenting to our tertiary care center with Covid-19 infection. Global burden was around 14 million Covid-19 positive cases with .5 million deaths and rising as per WHO update. A descriptive analytical cross-sectional study was carried out from June 1st to 30th, 2020 in a tertiary care center. Patients who tested positive by Reverse Transcriptase-Polymerase chain reaction were included in the study and clinical characteristics and outcome of the patients were analyzed along with impact on quality-of-life. Sample size was 250. Mean age was around 41 years, with age range from 15 to 75 years. Gender ratio was 1:2.4, with male preponderance. Most common presenting symptom was throat pain (60%). Rhinorrhea and sneezing complaints were not recorded. Clinical categorization was done and scored accordingly. Clinical outcomes of above patients showed complication rate 5.2%, mortality rate .8%, with discharge and recovery rate being rate 94.8% and 96% respectively. Fear of COVID-19 scale was used to assess quality-of-life impact. We found throat pain was the most common symptom in our study. No cases reported with rhinorrhea/sneezing. Good recovery rate noted. Quality-of-life impacted. © Association of Otolaryngologists of India 2020.Entities:
Keywords: Covid-19; DEMOGRAPHICS; Fear of COVID-19 scale; Outcomes; Quality-of-life; RT-PCR; SARS-CoV-2
Year: 2020 PMID: 32953634 PMCID: PMC7491595 DOI: 10.1007/s12070-020-02144-w
Source DB: PubMed Journal: Indian J Otolaryngol Head Neck Surg ISSN: 2231-3796
Clinical categorization
| Sr. no. | Criteria | Category A | Category B | Category C |
|---|---|---|---|---|
| 1 | Pulse/min | 60–100 | 100–120 | > 120 |
| 2 | Systolic blood pressure | > 120 | 100–120 | < 100 |
| 3 | Diastolic blood pressure | > 80 | 70–80 | < 70 |
| 4 | SpO2 | > 95% without O2 | > 95% with O2 | < 95% with O2 |
| 5 | Respiratory rate/min | < 18 | 18–24 | > 24 |
| 6 | Co-morbid | ± | + | + |
Category specific investigation panel
| Sr. no. | Category A | Category B | Category C |
|---|---|---|---|
| 1 | Complete blood count | Category A + | Category B + |
| 2 | Erythrocyte sedimentation rate | Arterial blood gas analysis | Serum IL-6 |
| 3 | Random blood sugar | D-dimer | |
| 4 | HBA1C | Serum ferritin | |
| 5 | Renal Function Test | CT thorax | |
| 6 | Liver Function Test | ||
| 7 | Urine routine | ||
| 8 | Chest X-ray | ||
| 9 | ECG | ||
| 10 | C-reactive protein |
Category-wise treatment protocol
| Sr. no. | Category A | Category B | Category C |
|---|---|---|---|
| 1 | T. Azithromycin 500 mg OD 5 days | Category A + | Category B + |
| 2 | T. Vitamin C 500 mg OD 10 days | Inj. Enoxaparin 40 mg SC BD (if D-Dimer elevated) | Inj. Cefaperazone + Sulbactam 1.5gm IV BD |
| 3 | T. Zinc 50 mg OD 10 days | T. Favipiravir 1600 BD day 1, 800 mg BD days2-13 | Inj. Methyl Prednisolone 125 mg IV OD |
| 4 | T. Paracetamol 650 mg SOS | Inj. Tocilizumab 8 mg/Kg (if IL6 elevated) | |
| 5 | T. Vitamin-D3 1000 IU OD 10 days | Inj. Remdesivir 200 mg IV on day 1, 100 mg IV from day 2–10 |
Study demographics
| Sr. no. | Parameter | Value | |
|---|---|---|---|
| 1 | Age range (years) | 15–75 | |
| Mean age (years) | 41.13 ± 9.93 | ||
| Sex ratio (M:F) | 2.4:1 | ||
| Education | High-school | 105 (42%) | |
| Graduate studies | 134 (53.6%) | ||
| Post-graduate studies | 11 (4.4%) | ||
| Marital status | Married | 187 (74.8%) | |
| Single | 61 (24.4%) | ||
| Widow(er) | 2 (.8%) | ||
| Employment during lockdown | Employed | 138 (55.2%) | |
| Employed—work from home | 10 (4%) | ||
| Un-employed | 102 (40.8%) | ||
| Risk category | A—No breathlessness | 237 (94.8%) | |
| B1—Breathless with > 95% SPO2 without O2 | 6 (2.4%) | ||
| B2—Breathless with > 95% SPO2 with O2 | 2 (.8%) | ||
| C—Breathless with < 95% SPO2 with O2 | 5 (2%) | ||
| Morbidity profile | Co-morbidity | 144 (57.6%) | |
| No co-morbidity | 106 (42.4%) | ||
| Smoking | Current | 93 (37.2%) | |
| Family member with covid-19 | No | 213 (85.2%) | |
| Yes | 37 (14.8%) | ||
Fig. 1Co-morbidity profile
Fig. 2Clinical presentation
Paired t test mean values
| Parameter | Mean | SD | SE mean | |
|---|---|---|---|---|
| Pair 1 | PreRx_FCV-19S_Item1 | 4.7080 | .59342 | .03753 |
| PostRx_FCV-19S_Item1 | 1.3640 | .89145 | .05638 | |
| Pair 2 | PreRx_FCV-19S_Item2 | 4.6000 | .74446 | .04708 |
| PostRx_FCV-19S_Item2 | 2.1720 | .78029 | .04935 | |
| Pair 3 | PreRx_FCV-19S_Item3 | 4.0320 | .45586 | .02883 |
| PostRx_FCV-19S_Item3 | 1.3640 | .86400 | .05464 | |
| Pair 4 | PreRx_FCV-19S_Item4 | 4.8400 | .42794 | .02707 |
| PostRx_FCV-19S_Item4 | 1.3480 | .92429 | .05846 | |
| Pair 5 | PreRx_FCV-19S_Item5 | 3.9800 | .45213 | .02859 |
| PostRx_FCV-19S_Item5 | 4.9680 | .17635 | .01115 | |
| Pair 6 | PreRx_FCV-19S_Item6 | 3.9320 | .42908 | .02714 |
| PostRx_FCV-19S_Item6 | 4.1200 | .32561 | .02059 | |
| Pair 7 | PreRx_FCV-19S_Item7 | 3.6920 | .67450 | .04266 |
| PostRx_FCV-19S_Item7 | 2.1280 | .55935 | .03538 | |
| Pair 8 | TotalPreRx_FCV-19S_All-items | 29.7840 | 1.44280 | .09125 |
| TotalPostRx_FCV-19S_All-items | 17.4640 | 3.75675 | .23760 | |
Paired t test mean differences
| Parameter | Paired sample tests—paired differences | df | Sig. (2-tailed) | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Mean differences | SD | SE mean | 95% confidence interval of the difference | ||||||
| Lower | Upper | ||||||||
| Pair 1 | PreRx–PostRx FCV-19S_Item1 | 3.34400 | 1.03826 | .06567 | 3.21467 | 3.47333 | 50.925 | ||
| Pair 2 | PreRx–PostRx FCV-19S_Item2 | 2.42800 | 1.02421 | .06478 | 2.30042 | 2.55558 | 37.482 | ||
| Pair 3 | PreRx–PostRx FCV-19S_Item3 | 2.66800 | .93878 | .05937 | 2.55106 | 2.78494 | 44.936 | ||
| Pair 4 | PreRx–PostRx FCV-19S_Item4 | 3.49200 | .98683 | .06241 | 3.36908 | 3.61492 | 55.950 | 249 | |
| Pair 7 | PreRx–PostRx FCV-19S_Item7 | 1.56400 | .80029 | .05061 | 1.46431 | 1.66369 | 30.900 | ||
| Pair 8 | TotalPreRx_FCV-19S–TotalPostRx_FCV-19S | 12.32000 | 3.64950 | .23081 | 11.86540 | 12.77460 | 53.376 | ||
Test values of Item Pair 5 and 6 in the FCV-19S scale have been highlighted as the mean differences between Pre- and Post-Treatment were negative. Though the p value was statistically significant (p < 0.001), the end-point was that in Items '5' and '6', quality-of-life status was poorer than the initial record
Fig. 3Correlation graph between FCV-19S amd admission clinical value